Skip to content

Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)

Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06503640
Enrollment
100
Registered
2024-07-16
Start date
2023-07-01
Completion date
2025-12-31
Last updated
2024-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Index of Microvascular Resistance

Brief summary

The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80.

Interventions

None listed

Sponsors

China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* presence of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \>0.80

Exclusion criteria

1. acute myocardial infarction 2. significant valvular heart disease 3. advanced chronic kidney disease 4. patients with significant epicardial coronary artery stenosis (\>70% in major vessels by diagnostic coronary angiography) needing percutaneous coronary intervention 5. patients unable to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
MACE in 12 months12 monthsmajor adverse cardiovascular events 12 months, including cardiac death, myocardial infarction, and readmission for angina.

Countries

China

Contacts

Primary ContactZhaoxue Sheng, Doctor
shengzhaoxue@163.com+86-15600268925

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026